Brain-Derived Tau in Blood: the Future of Alzheimer’s Disease Diagnosis?
Recently published in Brain, Gonzalez-Ortiz et al. report the design and development of a novel blood-based biomarker specific to brain-derived tau. In this blog post, we dive into the advantages of their novel immunoassay over those that are commercially available, as well as its future implications for Alzheimer’s disease diagnosis.
#ExpertAnswers: Dennis Turner on the Metabolics of Dementia
Dennis Turner delves into dementia syndrome, the metabolic changes that occur, and the importance of proper physiological monitoring of animal models.
Strategic Approaches to Age-Related Metabolic Insufficiency and Transition into Dementia Syndrome
In this webinar, Dr. Dennis Turner delves into dementia syndrome, the metabolic changes that occur, and the importance of proper physiological monitoring of animal models.
#ExpertAnswers: Louise Parr-Brownlie and Conor Underwood on Optogenetic Stimulation
Louise Parr-Brownlie and Conor Underwood discuss the impact of acute optogenetic stimulation for the treatment of Parkinson's disease in a rat model.
Optogenetic Stimulation for Parkinson’s Research: Recovering Movement in an Animal Model
Join Louise Parr-Brownlie, PhD and Conor Underwood, PhD for a review of implantable optogenetics to replace deep brain stimulation, a surgical procedure overview, and a discussion about the impact of acute optogenetic stimulation for the treatment of Parkinson's disease in a rat model.
Cutting Edge Conversations 2022
The Cutting Edge Conversations series offers a deep dive into specific research areas and focused insights regarding market-relevant processes from respected firms in the industry.
Cutting Edge Conversations: Fighting Neurodegenerative Diseases
Evelyn Pyper, MPH, discusses how a patient-centered approach to real-world data collection and evidence generation can transform research in neurodegeneration.
